Who is the CEO of Regeneron Pharmaceuticals?

Leonard S. Schleifer, since 1988, as the AsOf record states with its sources.

Record

Regeneron Pharmaceuticals as of November 9, 2026 · AsOf

organization

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is an American pharmaceutical company, headquartered in Tarrytown. Its CEO is Leonard S. Schleifer, since 1988. It reported revenue of $14.34B for the period ended December 31, 2025.

CEO: Leonard S. Schleifer since 1988 sec.gov
CFO: Christopher Fenimore sec.gov
Headquarters: Tarrytown sec.gov
Revenue: $14.34B to 2025-12-31 sec.gov
Ticker: REGN · Nasdaq sec.gov

Read the record as of a date

State as of 2026-11-09

7 assertedThe record stands behind this value for the day asked: two independent sources agree, or a primary source states it (alone, at confidence 0.7 or more). Everything else stays on the record, labelled.More in About → facts

Regeneron Pharmaceuticals: state as of 2026-11-09, one row per fact with its value, date, confidence and sources
fact	value	valid fromThe day the value took effect, not the day it was published. A period figure (a year's revenue) is dated at the period's end.More in About →	confidenceHow well the sources support the value, from 0 to 1. A single primary source is asserted from 0.7; nothing below 0.5 is asserted; a dead or disagreeing source lowers it.More in About →	sourcesPrimary: the entity's own filing, feed or site. Secondary: a publisher reporting it. Each claim links every source it has, with the passage that states the value where one was read.

Latest

1 dated event · full timeline →

2026-10-01 · agreementagreement

sec.gov

Financials

latest period on record · change vs prior year

Revenue

$14.34B

2025-12-31+1.0%

every revenue figure →

Net income

$4.50B

2025-12-31+2.1%

every net income figure →

Operating income

$3.58B

2025-12-31-10.3%

every operating income figure →

Total assets

$44.41B

2026-09-30+10.5%

Cash

$3.66B

2026-09-30+46.0%

As reported in the linked filings, which may be restated. Not investment advice.

State changes since 2026-05-13

21 changes · supersededA later claim replaced it: it keeps its end date and a pointer to the claim that replaced it, and is never deleted.More in About →

2026-09-30 · quarterly revenuequarterly revenue

sec.gov: 1 source for quarterly revenue, claim clm_15BDC7B1496E

2026-09-30 · total equitytotal equity

sec.gov: 1 source for total equity, claim clm_24A29A7153C0

2026-09-30 · quarterly operating incomequarterly operating income

sec.gov

About this record

Identifiers7 keys · schema.org snippet

AsOf ID: ent_regeneron-pharmaceuticals
Wikidata: Q7308054
SEC CIK: 0000872589
fiscal year end: 12-31
SIC industry: Pharmaceutical Preparations (2834)
incorporated in: NY
ticker: REGN

Cite this record in schema.org

"sameAs": ["https://www.wikidata.org/wiki/Q7308054", "https://asof.is/record/regeneron-pharmaceuticals"],
"identifier": { "@type": "PropertyValue", "propertyID": "asof", "value": "ent_regeneron-pharmaceuticals" }

Paste into the entity's JSON-LD. Why and how.

Sources on this entity1 site · 515 citations

sec.govprimary · 515

Get this recordmarkdown · JSON · MCP

/record/regeneron-pharmaceuticals.md

515 claims on record, 23 currently valid, 492 superseded. Last change 2026-10-01.

quarterly net income	1,948,700,000 United States dollar 2026-09-30sec.gov: 1 source for quarterly net income, claim clm_DEF587D6916A	2026-09-30	0.95	sec.gov: 1 source for quarterly net income, claim clm_DEF587D6916A
quarterly operating income	2,048,200,000 United States dollar 2026-09-30sec.gov: 1 source for quarterly operating income, claim clm_4585DB96888D	2026-09-30	0.95	sec.gov: 1 source for quarterly operating income, claim clm_4585DB96888D
quarterly research and development	1,794,700,000 United States dollar 2026-09-30sec.gov: 1 source for quarterly research and development, claim clm_4D8C13296D0A	2026-09-30	0.95	sec.gov: 1 source for quarterly research and development, claim clm_4D8C13296D0A
quarterly revenue	2026-09-30sec.gov: 1 source for quarterly revenue, claim clm_15BDC7B1496E	2026-09-30	0.95	sec.gov: 1 source for quarterly revenue, claim clm_15BDC7B1496E
research and development	2025-12-31sec.gov: 1 source for research and development, claim clm_1819F20C7CC4	2025-12-31	0.95	sec.gov: 1 source for research and development, claim clm_1819F20C7CC4
shares outstanding	2012-07-13sec.gov: 1 source for shares outstanding, claim clm_24C3500A1DEF	2012-07-13	0.95	sec.gov: 1 source for shares outstanding, claim clm_24C3500A1DEF
total equity	2026-09-30sec.gov: 1 source for total equity, claim clm_24A29A7153C0	2026-09-30	0.95	sec.gov: 1 source for total equity, claim clm_24A29A7153C0